Roche Reports Updated IMpassion130 Data for Tecentriq in Triple-Negative Breast Cancer

Roche today presented updated overall survival data from the Phase 3 IMpassion130 trial evaluating Tecentriq (atezolizumab) plus nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer. The updated data showed a clinically meaningful improvement in overall survival in the PD-L1 positive subgroup, with a median overall survival of 25.0 months compared to 18.0 months in the placebo arm.